Free Trial

Astellas Pharma (OTCMKTS:ALPMY) Sets New 52-Week Low - Time to Sell?

Astellas Pharma logo with Medical background

Astellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report) hit a new 52-week low during trading on Friday . The company traded as low as $9.00 and last traded at $9.19, with a volume of 261280 shares. The stock had previously closed at $9.22.

Astellas Pharma Price Performance

The company's 50 day moving average price is $9.63 and its 200 day moving average price is $10.22. The company has a debt-to-equity ratio of 0.39, a quick ratio of 0.80 and a current ratio of 1.04. The company has a market cap of $16.18 billion, a price-to-earnings ratio of -40.63 and a beta of 0.31.

Astellas Pharma (OTCMKTS:ALPMY - Get Free Report) last issued its quarterly earnings results on Tuesday, February 4th. The company reported $0.30 EPS for the quarter. Astellas Pharma had a positive return on equity of 13.69% and a negative net margin of 3.10%. On average, equities research analysts predict that Astellas Pharma Inc. will post 0.42 earnings per share for the current fiscal year.

About Astellas Pharma

(Get Free Report)

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.

See Also

Should You Invest $1,000 in Astellas Pharma Right Now?

Before you consider Astellas Pharma, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Astellas Pharma wasn't on the list.

While Astellas Pharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Top Nuclear Stocks To Buy Now Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Palantir’s Big Week Reveals a Rare Growth Story in a Shaky Market
Buy the Fear: 3 Down Stocks That Could 10x Your Profits
Congress Bought THESE Stocks as Tariffs Tanked the Market

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines